(19) World Intellectual Property Organization International Bureau



(43) International Publication Date 24 February 2005 (24.02.2005)

(10) International Publication Number WO 2005/016339 A1

- (51) International Patent Classification7: A61K 31/425, 31/50, 31/497, 31/44, 31/42
- (21) International Application Number:

PCT/US2003/023082

- (22) International Filing Date: 24 July 2003 (24.07.2003)
- (25) Filing Language:

English

(26) Publication Language:

English

- (71) Applicant (for all designated States except US): CASE WESTERN RESERVE UNIVERSITY [US/US]; 10900 Euclid Avenue, Cleveland, OH 44106-7219 (US).
- (72) Inventors; and
- (72) Inventors/Applicants (for US only): LANDRETH, Gary [US/US]; 2829 Southington Road, Shaker Heights, OH 44120 (US). COMBS, Colin (US/US); 14300 Cedar Road, Apartment 101, University Heights, OH 44121 (US). HIRSCH, Ettlene [—/—]; Paris (FR). HENEKA, Michael [—/—]; Germany (DE). BREIDERT, Tilo [—/—]; Paris (FR).

 BREIDERT, Tilo [—/—]; Paris (FR).

 With international search report on the "Guidance Road other abbreviations," appearing at the beginning of each regular issue of the PCT Gazette.

 (54) Title: METHODS FOR THE TREATMENT OF PARKINSON'S DISEASE

 (57) Abstruct: The present invention relates to methods and compositions for treating Parkinson's disease and for treating subjects susceptible to Parkinson's disease. In particular, the present invention provides agents that slow the progression of dopaminergic neuron loss in the substantia nigra, and that reduce the inflammatory responses of microglial cells and astrocytes in the substantia (75) Inventors/Applicants (for US only): LANDRETH, Gary

- (74) Agents: HALSTEAD, David, P. et al.; Ropes & Gray LLP, One International Place, Boston, MA 02110-2624
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, I.S, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

susceptible to Parkinson's disease. In particular, the present invention provides agents that slow the progression of dopaminergic neuron loss in the substantia nigra, and that reduce the inflammatory responses of microglial cells and astrocytes in the substantia